The latest update is out from Aura Biosciences Inc ( (AURA) ).
Aura Biosciences Inc. announced the departure of Julie Feder as Chief Financial Officer effective October 25, 2024, with no disputes regarding the company’s operations or financial reporting. Feder will provide consulting services until the end of the year, with benefits such as continued salary and severance pay. Meanwhile, Amy Elazzouzi steps in as interim principal financial officer and interim principal accounting officer, bringing her extensive financial experience within the company since 2015 and previous roles in the industry. Her compensation has been adjusted to reflect her new responsibilities while she is eligible for an annual performance bonus and indemnification agreement.
Learn more about AURA stock on TipRanks’ Stock Analysis page.
